Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 23, Issue 4, 2004, Pages 233-242

  Edwards, G ^a,b   Krishna, S ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; DIETHYLCARBAMAZINE; HALOFANTRINE; IVERMECTIN; MEFLOQUINE; MELARSOPROL; PRAZIQUANTEL; PRIMAQUINE DERIVATIVE; PYRIMETHAMINE; QUININE; QUININE DERIVATIVE; QUINOLINE DERIVATIVE; SULFADOXINE; TETRACYCLINE DERIVATIVE;

AFRICAN TRYPANOSOMIASIS; AREA UNDER THE CURVE; BAYES THEOREM; BIOMASS; CHAGAS DISEASE; DENGUE; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FILARIASIS; GENE AMPLIFICATION; HUMAN; LABORATORY TEST; LEISHMANIASIS; MALARIA; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; ONCHOCERCIASIS; PARASITOSIS; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SCHISTOSOMIASIS;

ADMINISTRATION, ORAL; ANTIPARASITIC AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PARASITIC DISEASES; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 2442640129     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-004-1113-9     Document Type: Review

References (54)

1. Stephenson LS, Latham MC, Ottesen EA (2000) Malnutrition and parasitic helminth infections. Parasitology 121 (Suppl): S23-S38
2. Stich AH, Abel P, Krishna S (2002) Human African trypanasomiasis. Brit Med J 325:203-206
3. Stich AH, Barrett M, Krishna S (2003) Waking up to sleeping sickness. Parasitol Today 19:195-197
4. White NJ (1999) Antimalarial drug resistance and combination chemotherapy. Phil Trans R Soc Lond B 354:739-749
5. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, et al (2002) Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419:498-511
6. Missinou MA, Borrmann S, Schindler A, Issifou S, Adegnika AA, Matsiegui PB, Binder R, Lell B, Wiesner J, Baranek T, Jomaa H, Kremsner PG (2002) Fosmidomycin for malaria. Lancet 360:1941-1942
7. Ridley RG (2002) Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415:686-693
8. Evans WE, McLeod HL (2003) Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 348:538-549
9. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348:529-537
10. Krishna S, Planche T, Agbenyega T, Woodrow C, Agranoff D, Bedu-Addo G, Owusu-Ofori AK, Appiah JA, Ramanathan S, Mansor SM, Navaratnam V (2001) Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrob Agents Chemother 45:509-516
11. Edwards G, Winstanley PA, Ward SA (1994) Clinical pharmacokinetics in the treatment of tropical disease: some applications and limitations. Clin Pharmacokinet 27:150-165
12. Supanaranond W, Davis TME, Pukrittayakamee S, Silamut K, Karbwang J, Molunto P, Chanond, L, White NJ (1991) Disposition of oral quinine in acute falciparum malaria Eur J Clin Pharmacol 40:49-52
13. Watt G, White NJ, Padre L, Ritter W, Fernando MT, Ranoa CP, Laughlin LW (1998) Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease J Infect Dis 157:530-535
14. Field JW, Sandosham AA, Yap LF (1963) Technical miscellanea. The microscopical diagnosis of human malaria. I. A morphological study of the erythrocytic parasites in thick blood films, 2nd edn. Institute of Medical Research, Federation of Malaya, Kuala Lumpur
15. Field JW, Shute PG (1956) The microscopic diagnosis of human malaria - a morphological study of the erythrocytic parasite. Government Press, Kuala Lumpur
16. White NJ, Krishna S (1989) Treatment of malaria: some considerations and limitations of current methods of assessment. Trans R Soc Trop Med Hyg 83:767-777
17. Planche T, Krishna S, Kombila M, Engel K, Faucher J, Ngou-Milama E, Kremsner P (2001) A comparison of laboratory methods for the assessment of children with malaria. Am J Trop Med Hyg 65:599-602
18. Chiodini P (2003) Babesiosis. In: Cook G, Zumla A (eds) Manson's tropical diseases, 21st edn, vol. 1. Elsevier Science, pp 1297-1301
19. Krishna S, Waller D, Kuile F ter, Kwiatkowski D, Crawley J, Craddock CFC, Nosten F, Chapman D, Brewster D, Holloway PA, White NJ (1994) Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 88:67-73
20. Silamut K, White NJ (1993) Relation of the stage of parasite development in the peripheral blood to prognosis in severe malaria. Trans R Soc Trop Med Hyg 87:436-443
21. Amodu OK, Adeyemo AA, Olumese PE, Gbadegesin RA (1998) Intraleucocytic malaria pigment and clinical severity of malaria in children. Trans R Soc Trop Med Hyg 92:54-56
22. Metzger WG, Mordmüller BG, Kremsner PG (1995) Malaria pigment in leucocytes. Trans R Soc Trop Med Hyg 89:637-638
23. Phu NH, Day N, Diep PT, Ferguson DJP, White NJ (1995) Intraleucocytic malaria pigment and prognosis in severe malaria. Trans R Soc Trop Med Hyg 89:200-204
24. Braun-Munzinger RA, Southgate BA (1992) Repeatability and reproducibility of egg counts of Schistosoma haematobium in urine. Trop Med Parasitol 43:149-154
25. Cheever AW, Kamel IA, Elwi AM, Mosimann JE, Danner R (1997) Schistosoma mansoni and S. haematobium infections in Egypt. II. Quantitative parasitological findings at necropsy. Am J Trop Med Hyg 26:702-716
26. Pepin J, Milord F, Guern C, Mpia B, Ethier L, Mansinsa D (1989) Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in Gambiense sleeping sickness. Lancet i:1246-1250
27. Cooper PJ, Guderian RH, Prakash D, Remick DG, Espine I, Nutman TB, Taylor DW, Griffin GE (1996) RANTES in onchocerciasis: changes with ivermectin treatment. Clin Exp Immunol 106:462-467
28. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ (2000) Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44:1680-1685
29. White NJ (2002) The assessment of antimalarial drug efficacy. Trends Parasitol 18:458-464
30. Day NP, Pham TD, Phan TL, Dinh XS, Pham PL, Ly VC, Tran TH, Nguyen TH, Bethell DB, Nguyan HP, Tran TH, White NJ (1996) Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood 88:4694-4700
31. White NJ (1997) Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41:1413-1422
32. Kuile FO ter, White NJ, Holloway PA, Pasvol G, Krishna S (1993) Plasmodium falciparum: In vitro studies of the pharmacodynamic properties of antimalarials used for the treatment of severe malaria. Exp Parasitol 76:85-95
33. Watt G, Shanks GD, Phintuyothin P (1992) Prognostic significance of rises in parasitaemia during treatment of falciparum malaria. Trans R Soc Trop Med Hyg 86:359-360
34. Nealon C, Dzeing A, Muller-Romer U, Planche T, Sinou V, Kombila M, Kremsner PG, Parzy D, Krishna S (2002) Intramuscular bioavailability and clinical efficacy of artesunate in Gabonese children with severe malaria. Antimicrob Agents Chemother 6:3933-3939
35. Burri C, Baltz T, Giroud C, Doua F, Welker HA, Brun R (1993) Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 39:225-234
36. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R (2000) Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355:1419-1425
37. Awadzi K, Adjepon-Yamoah KK, Edwards G, Orme ML'E, Breckenridge AM, Gilles HM (1996) The effect of moderate urine alkalinisation on low-dose diethylcarbamazine therapy in patients with onchocerciasis. Br J Clin Pharmacol 21:669-676
38. Edwards G, Dingsdale A, Helsby NA, Orme ML'E, Breckenridge AM (1988) Relative systemic availability of ivermectin after administration as capsule, tablet and oral solution. Eur J Clin Pharmacol 35:681-684
39. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu B, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE (2000) Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 6:861-871
40. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D (2001) A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344:257-263
41. Price R, Cassar CA, Brockman A, Duraisingh M, van Vugt M, White NJ, Nosten F, Krishna S (1999) Pfmdr1 gene amplification and multidrug-resistant Plasmodium falciparum on the north west border of Thailand. Antimicrob Agents Chemother 43:2943-2949
42. Doenhoff MJ, Kusel JR, Coles GC, Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 96:465-469
43. Dull HB (1990) Mectizan donation and the Mectizan Expert Committee. Acta Leiden 59:399-403
44. Awadzi K (1993) Drug surveillance: international cooperation past, present and future. In: Proceedings of the XXVIIth CIOMS (Council for International Organisation of Medical Sciences) Confererence, Geneva, 14-15 September 1993, pp 36-140
45. World Health Organisation (1995) Onchocerciasis and its control. Report of a WHO expert committee on onchocerciasis control. Tech Report Ser 852:1-104
46. Price RN, Nosten F, Luxemburger C, Kuile F ter, Paiphun L, Chongsuphajaisiddhi T, White NJ (1996) The effects of artemisinin derivatives on malaria transmissibility. Lancet 347:1654-1658
47. Kremsner PG, Krishna S (2002) Antimalarial cocktails - tropical flavours of the month. Lancet 360:1998-1999
48. Ezzet F, Vugt M van, Nosten F, Looareesuwan S, White NJ (2000) The pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute uncomplicated falciparum malaria. Antimicrob Agents Chemother 44:697-704
49. Vugt M van, Brockman A, Gemperli B, Luxemburger C, Gathman I, Royce C, Slight T, Looareesuwan S, White NJ, Nosten F (1998) Randomised comparison of artemether-benflumetol and artesunate-mefloquine in the treatment of multi-drug resistant falciparum malaria. Antimicrob Agents Chemother 42:135-139
50. Aarons L (1993) Sparse data analysis. Eur J Drug Metab Pharmacokinet 18:97-100
51. Simpson JA, Aarons L, White NJ (2001) How can we do pharmacokinetic studies in the tropics? Trans R Soc Trop Med Hyg 95:347-351
52. Vozeh S, Steimer JL, Rowland M, Morselli P, Mentre F, Balant LP, Aarons L (1996) The use of population pharmacokinetics in drug development. Clin Pharmacokinet 30:81-93
53. Simpson JA, Price R, Kuile F ter, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, Looareesuwan S, Aarons L, White NJ (1999) Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther 66:472-484
54. Krishna S, Nagaraja NV, Planche T, Agbenyega T, Bedo-Addo G, Ansong D, Owusu-Ofori A, Shroads AL, Henderson G, Hutson A, Derendorf H, Stacpoole PW (2001) Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother 245:1803-1809